SANDOZ RIOCIGUAT 1 MG
RIOCIGUAT : 1 MG · DIN 02533561 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is SANDOZ RIOCIGUAT?
SANDOZ RIOCIGUAT 1 MG contains RIOCIGUAT : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02533561, held by SANDOZ CANADA INCORPORATED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 29-Apr-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SANDOZ RIOCIGUAT used for?
Treatment of inoperable, persistent or recurrent CTEPH (WHO Group 4) and PAH (WHO Group 1) in adults (WHO Functional Class II or III).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02533561 |
|---|---|
| Brand name | SANDOZ RIOCIGUAT |
| Generic / active ingredient | RIOCIGUAT : 1 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 1 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C02KX05 RIOCIGUAT |
| AHFS class | 48:48.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Apr-2024 |
| Original market date | 2024-04-29 00:00:00 |
How is it administered?
Initial: 1 mg 3 times daily. Titrate by 0.5 mg every 2 weeks based on systolic BP (>=95 mmHg) to max 2.5 mg 3 times daily. Take 6-8 hours apart with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (section 11 header present but content missing), though standard pharmaceutical storage is implied.
How is it supplied?
HDPE bottles of 30 and 90 tablets; blisters of 42 tablets.
Contraindications
Concomitant use with PDE5 inhibitors, nitrates, nitric oxide donors, or other sGC stimulators; pregnancy and nursing; hypersensitivity; patients with PH-IIP.
Warnings and precautions
Risk of serious/fatal bleeding (hemoptysis); hypotension (vasodilator effects); reduced exposure in smokers; not recommended in PVOD. Monitor BP during titration.
What can be used instead?
Other Canadian products sharing ATC code C02KX05 RIOCIGUAT. 10 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ADEMPAS | 0.5 MG | TABLET | BAYER INC | MARKETED | DIN 02412764 |
| ADEMPAS | 1 MG | TABLET | BAYER INC | MARKETED | DIN 02412772 |
| ADEMPAS | 1.5 MG | TABLET | BAYER INC | MARKETED | DIN 02412799 |
| ADEMPAS | 2 MG | TABLET | BAYER INC | MARKETED | DIN 02412802 |
| ADEMPAS | 2.5 MG | TABLET | BAYER INC | MARKETED | DIN 02412810 |
| SANDOZ RIOCIGUAT | 0.5 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02533545 |
| SANDOZ RIOCIGUAT | 1.5 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02533588 |
| SANDOZ RIOCIGUAT | 2 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02533596 |
| SANDOZ RIOCIGUAT | 2.5 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02533618 |
Who else supplies RIOCIGUAT worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RIOCIGUAT appears in 101 registered pack listings across 12 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.